In July 2026, the World Health Organization (WHO) rolled out a landmark policy for the medical device industry: the inaugural list of transitional WHO Listed Authorities for Medical Devices (tWLAs-MD). Only 12 top-tier global regulatory bodies made the cut, including China’s National Medical Products Administration (NMPA).
This list marks a paradigm shift in global medical device regulation, phasing out the old Stringent Regulatory Authorities (SRA) framework originally designed for pharmaceuticals and vaccines, and ushering in the standardized WHO Listed Authority (WLA) evaluation system. For Chinese medical device manufacturers going global, this WHO-endorsed authoritative roster completely reshapes the underlying logic of worldwide registration, delivering a massive boost to the international credibility of domestic medical device registration certificates.
https://www.who.int/publications/m/item/list-of-transitional-wlas-for-medical-devices
For a long time, the WHO only established the SRA roster for pharmaceuticals and vaccines. No unified, globally recognized benchmark authority list existed specifically for medical devices. Without consistent standards for cross-border registration reliance and regulatory collaboration, manufacturers faced repeated technical reviews, prolonged approval timelines and exorbitant overseas compliance costs. Low- and middle-income countries, constrained by limited regulatory expertise and manpower, also struggled to bring high-quality medical devices to patients in a timely manner.
The WHO formally issued the tWLAs-MD interim list on July 14, 2026, serving as a transitional pathway toward permanent WLA accreditation with a five-year validity term. During the transition period, the WHO will continuously monitor and assess each authority’s regulatory performance: bodies meeting standards will upgrade to permanent WLA status, while underperforming ones will be removed from the roster. This creates a dynamic, transparent, performance-centric global regulatory evaluation system.
Regulatory Reliance, as defined by the WHO, forms the core value of this list: Regulatory authorities of any jurisdiction may fully reference complete review findings and inspection reports issued by tWLA-listed authorities. They only need to carry out supplementary assessments addressing local market-specific requirements, rather than launching full independent technical evaluations from scratch. Critically, each national regulator retains full independent authority and ultimate accountability for all products authorized for domestic sale, with no compromise to local safety oversight standards.
Over 70% of countries worldwide suffer shortages of regulatory staff and technical capabilities. Regulatory Reliance is the official industry solution promoted by the WHO, and the tWLAs-MD serves as the globally unified whitelist of reference regulators eligible for cross-jurisdictional reliance.
Two Industry-defining Takeaways
Brazil’s ANVISA Holds Exclusive Regulatory Voice in Latin America：Among over 30 Latin American nations, ANVISA is the only authority selected for the tWLA roster. For all regional jurisdictions implementing Regulatory Reliance mechanisms, approvals granted by ANVISA will serve as a priority reference basis. Launching registration in Brazil first before expanding across Latin America emerges as the optimal overseas market entry strategy.
As Latin America’s sole tWLA authority, ANVISA’s role as a regional regulatory benchmark will be further reinforced:
Traditional Isolated Pathway：Submit full standalone applications, complete independent clinical evaluations and undergo separate quality system audits for every jurisdiction. Each market takes 12–24 months to clear, with manpower and capital costs doubled.
Superposition Effect of Dual Policy Releases：The WHO defines the roster of authoritative reference regulators, while IMDRF provides actionable implementation tools. Interconnected global medical device regulation is an irreversible industry megatrend.
The long-term trend remains unambiguous: all nations face constraints on regulatory resources and share a core demand to eliminate redundant review work. Regulatory Reliance mechanisms will continue to gain global traction, and enterprises that proactively adopt tWLA-aligned registration roadmaps will capture first-mover market advantages.
The release of the WHO’s inaugural tWLA list for medical devices represents a major policy dividend for the internationalization of China’s medical device industry. The era of cross-border mutual recognition in global medical device regulation has officially begun. Mastery of the 12 WHO-recognized authoritative regulatory anchors will become a core competitive edge for domestic medical device manufacturers breaking into global markets. For further detailed consultation, please contact Wiselink.
